MCM
ALXN

MAI Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

MAI Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,189
Closed -$218K – 865
2021
Q2 		$218K Buy
+1,189
New +$204K ﹤0.01% 682
2021
Q1 		– Sell
-1,754
Closed -$274K – 790
2020
Q4 		$274K Sell
1,754
-354
-17% -$45.5K 0.01% 556
2020
Q3 		$241K Sell
2,108
-612
-23% -$66K 0.01% 510
2020
Q2 		$305K Sell
2,720
-225
-8% -$23.9K 0.01% 455
2020
Q1 		$264K Sell
2,945
-1,317
-31% -$129K 0.01% 455
2019
Q4 		$461K Sell
4,262
-2,507
-37% -$268K 0.01% 402
2019
Q3 		$663K Sell
6,769
-292
-4% -$32.9K 0.03% 310
2019
Q2 		$925K Buy
+7,061
New +$910K 0.04% 255
2017
Q2 		– Sell
-1,682
Closed -$204K – 477
2017
Q1 		$204K Sell
1,682
-3,028
-64% -$390K 0.01% 414
2016
Q4 		$576K Sell
4,710
-491
-9% -$60.1K 0.04% 247
2016
Q3 		$637K Buy
5,201
+920
+21% +$118K 0.05% 240
2016
Q2 		$500K Buy
4,281
+1,358
+46% +$193K 0.04% 271
2016
Q1 		$407K Buy
2,923
+273
+10% +$40.1K 0.03% 295
2015
Q4 		$505K Buy
2,650
+596
+29% +$104K 0.04% 270
2015
Q3 		$321K Buy
2,054
+549
+36% +$100K 0.02% 334
2015
Q2 		$272K Buy
+1,505
New +$260K 0.02% 386

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

MAI Capital Management's ALXN Position: Q3 2021 in Review

MAI Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,189 shares — an estimated $218K sold.

MAI Capital Management first reported a position in ALXN in Q2 2015 and held it in 16 quarters. The position peaked at $925K in Q2 2019. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • MAI Capital Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • MAI Capital Management sold 1,189 Alexion Pharmaceuticals shares in Q3 2021, an estimated $218K.
  • MAI Capital Management first reported a position in Alexion Pharmaceuticals in Q2 2015 and held it in 16 quarters.
  • MAI Capital Management's Alexion Pharmaceuticals position peaked at $925K in Q2 2019.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on MAI Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.